IN8BIO INC. - COMMON

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

11 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

11 Dec 2023 08:00:47 By Nasdaq GlobeNewswire

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

05 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

20 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

10 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 08:17:21 By Nasdaq GlobeNewswire

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

01 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

12 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

29 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

19 Sep 2023 07:03:33 By Nasdaq GlobeNewswire

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

15 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 15:15:37 By Nasdaq GlobeNewswire